Stories

This morning, TRIUMF welcomed BC Health Minister, Adrian Dix, into the Meson Hall, where he announced the province is investing $32 million through $21 million to BC Cancer for the new cyclotron and radiopharmacy laboratory and approximately $11 million to TRIUMF to advance research. In addition, the BC Cancer Foundation has provided $3.5 million to support capital investments and $15 million in funding for critical cancer research, for a total of $50.5 million.

As part of a memorandum of understanding (MOU) with General Fusion signed in October 2023, TRIUMF is undertaking the development of critical diagnostic technologies to support General Fusion’s Magnetized Target Fusion (MTF) demonstration, also called Lawson Machine 26 (LM26). 

QRT Inc. and the PIF & NIF team at TRIUMF are taking new steps to further strengthen a collaborative program of research and development at the laboratory’s neutron irradiation facilities (NIF), bolstering an existing memorandum of understanding (MOU) and bringing online new analysis technologies to improve test accuracy and efficiency.

TRIUMF is pleased to share the results of the ‘Evaluation of TRIUMF 2023-24', a deep-dive analysis conducted by the National Research Council (NRC) that assessed TRIUMF’s scientific excellence, social and economic impact, relevance, capacity, competency, facilities and governance.